Pediatric Allergy in the North-American Region

2 February 2025
9 July 2025
Pediatric Allergy in the North-American Region promotional image

North America has long been a vibrant hub for groundbreaking research in allergy and immunology driven by its pioneering multiple discoveries in the field, a strong tradition of scientific collaboration, and its rich and diverse patient populations with distinctive environmental exposures.

We are delighted to present this special issue of Pediatric Allergy and Immunology, which provides an inspiring glimpse into the future of pediatric allergy research in North America. The editors of PAI warmly invite researchers from across the region to contribute their work to the journal. We welcome submissions of original research, reviews, and case studies that advance our understanding of pediatric allergies and immunology within the North American context.

Submissions can be made via the Research Exchange Platform and will undergo a thorough peer-review process.

With this Virtual Issue, we feature a set of trailblazing studies which will debut in 2025. This collection highlights innovative research that is set to transform the field and address critical challenges in pediatric allergy and immunology.

We hope that this issue inspires your own work while fostering the understanding of this ever-evolving field.

Warm regards,
Ayobami Akenroye, Guest Editor, Associate Editor, PAI
Carmen Riggioni, Guest Editor, Associate Editor, PAI
Philippe Eigenmann, Editor-in-Chief, PAI

Original Article:

Open Access

Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)

Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)

Benralizumab treatment in children demonstrated predictable PK parameters and a reassuring safety profile, consistent with previous studies in adolescents and adults. Treatment with benralizumab resulted in a near-complete reduction in blood eosinophil counts from baseline. Exploratory clinical outcomes indicated numerical improvements in FEV1, CGIC, and PGIC-IA responses, as well as ACQ-IA score and exacerbation rates. Abbreviations: ACQ-IA, Asthma Control Questionnaire-Interviewer administered; BL, baseline; CGIC, Clinician Global Impression of Change; CI, confidence interval; EOT, end of treatment; FEV1, forced expiratory volume in 1 second; PGIC-IA, Patient Global Impression of Change-Interviewer administered; PK, pharmacokinetics; SE, standard error; VPC, visual predictive check.

Open Access

Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO

Nikolaos G. Papadopoulos Adnan Custovic Antoine Deschildre James E. Gern Antonio Nieto Garcia Michael Miligkos Wanda Phipatanakul Gary Wong Paraskevi Xepapadaki Ioana Agache Stefania Arasi Zeinab Awad El-Sayed Leonard B. Bacharier Matteo Bonini Fulvio Braido Davide Caimmi Jose A. Castro-Rodriguez Zhimin Chen Michael Clausen Timothy Craig Zuzana Diamant Francine M. Ducharme Motohiro Ebisawa Philippe Eigenmann Wojciech Feleszko Vincezo Fierro Alessandro Fiocchi Luis Garcia-Marcos Anne Goh René Maximiliano Gómez Maia Gotua Eckard Hamelmann Gunilla Hedlin Elham M. Hossny Zhanat Ispayeva Daniel J. Jackson Tuomas Jartti Miloš Jeseňák Omer Kalayci Alan Kaplan Jon R. Konradsen Piotr Kuna Susanne Lau Peter Le Souef Robert F. Lemanske Michael Levin Mika J. Makela Alexander G. Mathioudakis Oleksandr Mazulov Mário Morais-Almeida Clare Murray Karthik Nagaraju Zoltan Novak Ruby Pawankar Marielle W. Pijnenburg Helena Pite Paulo M. Pitrez Petr Pohunek David Price Alfred Priftanji Valeria Ramiconi Daniela Rivero Yeverino Graham Roberts Aziz Sheikh Kun-Ling Shen Zsolt Szepfalusi Ioanna Tsiligianni Mirjana Turkalj Steve Turner Tetiana Umanets Arunas Valiulis Susanne Vijveberg Jiu-Yao Wang Tonya Winders Dong Keon Yon Osman M. Yusuf Heather J. Zar WAO Pediatric Asthma Committee
Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO

Letter: